Outcomes After Lung Re-Transplantation for Restrictive Allograft Syndrome Have Not Improved Over Two Decades

This retrospective United Network for Organ Sharing (UNOS) database study evaluated the evolving strategies and outcomes of lung re-transplantation for restrictive allograft syndrome (RAS) over two decades (2005–2025), stratifying 293 patients into early (2005–2015) and contemporary (2016–2025) cohorts. The authors sought to determine if modern surgical advances improved long-term prognosis and found that while contemporary practice favors bilateral re-transplantation and utilizes significantly more advanced perioperative mechanical and renal support, five-year survival remains remarkably poor and statistically unchanged between eras (32.6 percent vs. 32.3 percent, p=0.93). Era 2 re-transplants were characterized by longer ischemia times and a significantly higher use of bilateral re-transplantation (65 percent vs 41 percent, p<0.001), with similar mortality. The authors suggest that surgical escalation fails to mitigate the intrinsic, likely immunological, drivers of RAS and thus technical feasibility must be weighed against expected futility, necessitating a paradigm shift toward early disease modification and stringent candidate selection rather than routine re-transplantation for advanced RAS.